Skip to main content
SpringerLink
Log in

Clinical trials

MSC therapy for diabetic kidney disease and nephrotic syndrome

  • News & Views
  • Published:

From Nature Reviews Nephrology

View current issue Sign up to alerts

New clinical studies suggest that mesenchymal stem cell (MSC) therapy can have positive clinical effects, potentially via immunomodulation, in patients with diabetic nephropathy or nephrotic syndrome. These trials suggest that the therapy is safe, but adverse reactions highlight the need to examine the source and functional attributes of MSCs closely.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Factors that affect the function and efficacy of MSC therapy.

References

  1. Rožanc, J. et al. Mesenchymal stem cells isolated from paediatric paravertebral adipose tissue show strong osteogenic potential. Biomedicines 10, 378 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  2. Perico, N. et al. Safety and preliminary efficacy of mesenchymal stromal cell (ORBCEL-M cell) therapy in diabetic kidney disease: a randomized clinical trial (NEPHSTROM). J. Am. Soc. Nephrol., https://doi.org/10.1681/ASN.0000000000000189 (2023).

    Article  PubMed  Google Scholar 

  3. Vivarelli, M. et al. A phase 1 study of autologous mesenchymal stromal cells for severe steroid-dependent nephrotic syndrome. JCI Insight 8, e169424 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  4. Packham, D. K., Fraser, I. R., Kerr, P. G. & Segal, K. R. Allogeneic mesenchymal precursor cells (MPC) in diabetic nephropathy: a randomized, placebo-controlled, dose escalation study. EBioMedicine 12, 263–269 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Morello, W. et al. First clinical application of cord blood mesenchymal stromal cells in children with multi-drug resistant nephrotic syndrome. Stem Cell Res. Ther. 13, 420 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Thompson, M. et al. Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: an updated systematic review and meta-analysis. EClinicalMedicine 19, 100249 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  7. Wu, Z. et al. Thromboembolism induced by umbilical cord mesenchymal stem cell infusion: a report of two cases and literature review. Transplant. Proc. 49, 1656–1658 (2017).

    Article  CAS  PubMed  Google Scholar 

  8. Starc, N. et al. Phenotypic and functional characterization of mesenchymal stromal cells isolated from pediatric patients with severe idiopathic nephrotic syndrome. Cytotherapy 20, 322–334 (2018).

    Article  CAS  PubMed  Google Scholar 

  9. Joswig, A. J. et al. Repeated intra-articular injection of allogeneic mesenchymal stem cells causes an adverse response compared to autologous cells in the equine model. Stem Cell Res. Ther. 8, 42 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  10. Liau, L. L., Ruszymah, B. H. I., Ng, M. H. & Law, J. X. Characteristics and clinical applications of Wharton’s jelly-derived mesenchymal stromal cells. Curr. Res. Transl. Med. 68, 5–16 (2020).

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work is partly supported by NIH grants DK120292 and HL158691.

Author information

Authors and Affiliations

  1. Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA

    Bo Lu & Lilach O. Lerman

  2. Department of Cardiology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China

    Bo Lu

Authors
  1. Bo Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lilach O. Lerman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lilach O. Lerman.

Ethics declarations

Competing interests

L.O.L. is an advisor to CureSpec and Ribocure Pharmaceuticals. B.L. declares no competing interests.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lu, B., Lerman, L.O. MSC therapy for diabetic kidney disease and nephrotic syndrome. Nat Rev Nephrol 19, 754–755 (2023). https://doi.org/10.1038/s41581-023-00776-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41581-023-00776-z

  • Springer Nature Limited

Search

Navigation